WO1997045592A1 - Schallschutzeinrichtung für gleise - Google Patents

Schallschutzeinrichtung für gleise Download PDF

Info

Publication number
WO1997045592A1
WO1997045592A1 PCT/AT1997/000109 AT9700109W WO9745592A1 WO 1997045592 A1 WO1997045592 A1 WO 1997045592A1 AT 9700109 W AT9700109 W AT 9700109W WO 9745592 A1 WO9745592 A1 WO 9745592A1
Authority
WO
WIPO (PCT)
Prior art keywords
plate
plates
partial
soundproofing device
support sections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT1997/000109
Other languages
German (de)
English (en)
French (fr)
Inventor
Bernhard Neumann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gmundner Fertigteile GmbH and Co KG
Original Assignee
Gmundner Fertigteile GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT93496A external-priority patent/AT403809B/de
Priority claimed from AT0101596A external-priority patent/AT405426B/de
Priority to HU9903612A priority Critical patent/HU221872B1/hu
Priority to US09/194,505 priority patent/US6253872B1/en
Priority to AT97922748T priority patent/ATE229595T1/de
Priority to EP97922748A priority patent/EP0901536B1/de
Priority to SI9730491T priority patent/SI0901536T1/xx
Priority to JP54125697A priority patent/JP3822641B2/ja
Application filed by Gmundner Fertigteile GmbH and Co KG filed Critical Gmundner Fertigteile GmbH and Co KG
Priority to CA002255946A priority patent/CA2255946C/en
Priority to AU28801/97A priority patent/AU738889B2/en
Priority to DK97922748T priority patent/DK0901536T3/da
Priority to DE59708955T priority patent/DE59708955D1/de
Publication of WO1997045592A1 publication Critical patent/WO1997045592A1/de
Anticipated expiration legal-status Critical
Priority to NO19985600A priority patent/NO316078B1/no
Ceased legal-status Critical Current

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01B—PERMANENT WAY; PERMANENT-WAY TOOLS; MACHINES FOR MAKING RAILWAYS OF ALL KINDS
    • E01B19/00—Protection of permanent way against development of dust or against the effect of wind, sun, frost, or corrosion; Means to reduce development of noise
    • E01B19/003—Means for reducing the development or propagation of noise

Definitions

  • the invention relates to a soundproofing device for tracks, with sound-absorbing plates mounted on the rails of the track, which are supported on the rails by elastic profiles, the plates arranged between the rails cantilevering the space between the rails. Furthermore, the invention relates to sound-absorbing panels for such a soundproofing device.
  • the plates arranged between the rails of the track consist of three layers or layers which are supported by elastic profiles on the rail foot, web and on the underside.
  • the upper layer consists of steel wire fabric that can be walked on, the edge of which is glued, welded or vulcanized into the profile.
  • the middle layer is designed as a sound absorption layer and consists of glass wool or rock wool. This sound absorption layer lies on the lower layer, which is designed as a perforated wall or grate and is supported in a recess in the profile in the region of the rail foot.
  • the panels are also arranged on the outside of the rail and angled upward at the ends in order to form a lateral soundproofing wall.
  • Such mineral wool panels have adequate sound absorption at high frequencies, but have inadequate sound absorption at low frequencies.
  • a further disadvantage of this construction is that the walkable perforated wall made of steel wire mesh can detach itself from its anchoring in the profiles at higher and repeated loads, so that the sound absorption layer underneath can be damaged.
  • the dust penetrating through the perforated wall can be deposited on the upper side of the sound absorption layer and thus the sound damping effect can deteriorate increasingly.
  • the invention has for its object to provide a soundproofing device for tracks with sound-absorbing plates, which has good sound absorption or damping over the entire frequency range essential for the sound level of rail traffic, with a permanent mechanical Strength of the device should be guaranteed.
  • the soundproofing device of the type mentioned at the outset in that the plates consist of particles of porous lightweight construction material which are joined together with a binder, and in that the plates have embedded reinforcement and are arranged uncovered.
  • the airborne noise emanating in particular from the wheels of a rail vehicle and from the rails is absorbed on the surface of the plates by the pores of the particles and can also be selected if a structure is left that leaves fine spaces between the particles, via spaces or channels between the particles penetrate deeper into the plate to gradually be completely dampened there.
  • the reinforcement of the panels also ensures that they can be walked on.
  • the top of the plates is structured, and even better results can be achieved if the structuring is irregular.
  • the top of the plates is preferably provided with ribs running parallel to the rails, which results in structuring that is simple to construct.
  • the ribs have a trapezoidal cross-section, since this makes it easier to absorb obliquely incident sound waves.
  • the wall of the cavity resonators and their sound openings are provided with a sound-absorbing structure, and / or if the wall of the cavity resonators and their tubular sound openings are provided with a sound-absorbing layer are provided.
  • the cavities forming the cavity resonators are designed to be open at the bottom and are covered with a lower plate.
  • the cavities forming the cavity resonators are designed to be open at the bottom and form a resonance cavity together with the track bedding.
  • the damped resonance frequency of the cavity resonators is within a frequency range from 150 to 1000 Hz, preferably between 500 and 1000 Hz.
  • a special embodiment is also provided in which the installation and removal of the plates to be provided between the two rails of a track can be accomplished in a very simple manner.
  • This embodiment of the soundproofing device is characterized in that the space lying between the two rails of a track is bridged with partial plates arranged in pairs, each of which engages with at least one supporting rib in the link chambers of the rails, the partial plates of each pair of plates at their mutually facing edges are supported on one another and in this case support sections and support sections are provided alternately in a meandering manner on each section plate along the edge facing the other section plate, the support sections being formed by depressions extending from the top of the plate and facing the other section plate and under the support sections from the underside of the plate, upward depressions are formed, which are complementary to the depressions of the support sections, and the support sections of a partial plate on the support sections the other partial plate and the support sections of the other partial plate rest on the supporting sections of the one partial plate.
  • the zones of the partial plates of each pair of plates to be joined in an articulated manner can simply be plugged together when the partial plates are unfolded, after which the partial plates can be inserted between the rails without problems by leveling the pair of plates, and the partial plates also become Loads not pushed apart.
  • a preferred type of the last-mentioned embodiment which is characterized in that projections and recesses shaped complementarily to the projections, into which the projections engage, are provided on those surfaces on which the partial plates of a pair of plates abut one another, for mutual locking of the partial plates, offers the advantage that the cohesion of the partial plates of a pair of plates is ensured even over very long periods of time even when unfavorable vibrations act on the partial plates.
  • Such a crowning can be formed on a partial plate by a surface section which extends from the edge facing the other partial plate of the pair of plates and extends away from the underside of the plate, and a subsequent surface section which approaches the underside of the plate. If one wishes to additionally provide a latching in such a configuration of the partial plates, it is advantageous if they are designed in such a way that projections pointing downward are provided on the end edges of the supporting sections and recesses complementary to these projections are provided on the supporting surfaces of the supporting sections.
  • An embodiment which is particularly favorable for the course of the leveling process when installing the partial plates and for achieving the most stable possible position of the two partial plates of a pair of plates relative to one another in the installed state characterized in that the cambered shaped wings are shaped according to a toothing which, up to the leveled position of the partial plates of the respective pair of plates, enables sliding or rolling movement of the facing wings and supporting surfaces towards one another and in the leveled position of these partial plates against one another Movement of these partial plates to each other blocks.
  • the reinforcement provided in the sub-panels extends over the panel surface and engages in the supporting sections and in the supporting sections and in the supporting ribs. It is also advantageous if one provides that an elastic or / or shock-absorbing insert or coating is provided between the wings provided on the support sections and the support surfaces provided on the support sections.
  • a sound-absorbing plate according to the invention is characterized in that the plate consists of particles made of porous lightweight material, which are joined together with a binder, that the plate has an embedded reinforcement, and that in the plate cavity resonators with a large area of the Plate directed tubular sound openings are formed, which large area to form the top is provided when installing the plate in the track. It is advantageous here if the cavities forming the cavity resonators are designed to be open and widening towards the large area that lies on the side of the plate facing away from the tubular sound openings. A further development is characterized in that the cavities forming the cavity resonators are covered with a lower plate on the side facing away from the tubular sound openings.
  • Embodiments of a plate designed according to the invention which are provided for the aforementioned formation with partial plates to be joined to form a pair of plates, are characterized in that the plate consists of particles of porous lightweight building material, which are joined together with a binder, so that the plate is an embedded one Reinforcement has that the plate is provided on one edge side with a support rib for engaging in the tab chambers of rails and on the edge side opposite this support rib has meandering succession of support sections and support sections, the support sections extending from the top of the plate and depressions extending to the edge are formed and under the support sections, from the underside of the plate, upward depressions are formed, which are complementary to the depressions of the support sections.
  • cavity resonators are formed in the plate with tubular sound openings directed towards a large area of the plate, which large area is provided for forming the upper side when the plate is installed in the track. It is also advantageous here if the reinforcement provided in the plate extends over the entire surface of the plate and extends into the support sections and into the support sections and into the support rib. If desired, the plates or partial plates can also be provided with a frame running along the edge, preferably consisting of metal or fiber-reinforced plastic.
  • FIG. 1 shows a plan view of a track with sound-absorbing plates arranged between the rails
  • FIG. 2 shows a section along the line II-II in Fig.l
  • 3 shows an embodiment of a plate in cross section
  • FIG. 4 shows an enlarged detail of the surface of the plate according to FIG. 2 or 3;
  • FIG. 5 shows an embodiment of a soundproofing device designed according to the invention with partial plates in a top view
  • FIG. 10 shows a variant with regard to the design of the support sections and the support sections in a sectional representation corresponding to FIG. 7,
  • FIG. 11 shows another embodiment of a soundproofing device designed according to the invention with partial panels, in a top view
  • FIG. 16 shows a variant with regard to the design of the support sections and the support sections of the partial plates in a sectional representation corresponding to FIG. 13.
  • sound-absorbing plates 3 are arranged next to one another in the longitudinal direction of the track between the rails 2.
  • the generally rectangular plates 3 have, on their two edges along the rails 2, projecting support ribs 4, which are interposed with elastic profiles 5, for example made of rubber or elastomer, support on the rail base 6, on the rail web 7 and on the underside of the rail head 8 of the rails 2.
  • the plates 3, the surface of which is shown enlarged in FIG. 4, consist of particles 9 made of porous lightweight material, which are joined together with a suitable binder.
  • Plastic granulate, granular or spherical and fired alumina particles, granular slag particles, or similar fired natural or artificially produced materials are used as the lightweight construction material, these particles being selectively connected with a suitable plastic binder or cement, so that small spaces or channels 10 remain, which allow air ducting and drainage of penetrating rain or melt water.
  • the panels 3 are provided with a reinforcement 11, for example made of steel or other metals, fiber-reinforced plastic, glass fiber mats or the like.
  • the surface of the plates 3 can be increased by structuring.
  • the top 12 of the plates 3 can be provided with ribs 13 which run parallel to the rails 2 and are spaced apart from one another and which, as shown in FIG. 3, have a trapezoidal cross section and a height a above the rail head 8 which are closed ⁇ not exceeding 5 cm.
  • the structure can also be irregular, for example by increasing or decreasing the spacing of the ribs 13 from one another.
  • a structuring of the top 12 for example, truncated cones, truncated pyramids, cylinders, cuboids, etc. can also be provided, which are arranged either at the same or at different distances from one another.
  • 3 cavity resonators 14 in the manner of the Helmholz resonator are formed in the plates, the tubular sound openings of which 15 are provided on the top 12 of the plates 3.
  • the cavities forming the cavity resonators 14 are frustoconical and open at the bottom, the openings formed thereby being covered by a sub-plate 16, for example glued to the plate 3, in order to form the cavity resonator 14 .
  • the cavities forming the cavity resonators 14 can also be designed to deviate from the shape of a truncated cone, for example spherical, cylindrical, pyramid-shaped, etc., in order to achieve a different frequency behavior in the case of sound absorption.
  • the volumes of the cavity resonators 14 and the dimensions of the tubular sound openings can be varied in order to achieve the desired frequency behavior or frequency absorption spectrum. As shown in FIG.
  • the tubular sound openings 15 open perpendicular to the top 12 of the plate 3.
  • the tubular sound openings 15 can also open at an angle to the top 12 of the plates 3 in order to be able to better absorb obliquely incident sound waves .
  • the plates 3 with the cavity resonators 14 can be produced in a rectangular shape in which positive shapes of the cavity resonators with attached pipe pieces for the sound openings are used, whereupon the mold is filled with the particles 9 and a binder and demolded after the binder has hardened becomes.
  • Prefabricated cavity resonators with attached pipe pieces as sound openings can also be used as positive forms, which either consist of a suitable sound-absorbing material or are provided on the inside with a layer of sound-absorbing material.
  • sound-absorbing plates with cavity resonators can also be provided on the outside of the rails 2.
  • the plate 18 shown in dash-dotted lines on the right rail 2 is at one End, similar to the plate 3 lying between rails 2, is supported on the rail 2 via an elastic profile 5 and at the other end via an elastic strip 19 and fixed by means of a fastening element, in particular a screw 20.
  • the plate 21 on the left rail 2, also shown with a dash-dotted line, is supported and fixed in the same way as the plate 18, but has an end region that is angled upwards on the outside in order to form a soundproofing wall.
  • the two plates 18, 21 likewise have reinforcement (not shown) and, if appropriate, a structure in the form of ribs (not shown). If desired, the plates can also be provided with a frame running along the edge.
  • the space 22 lying between the two rails 2 of a track 1 is filled or bridged with paired sound-absorbing partial plates 3a, 3b.
  • These sub-plates 3a, 3b have support ribs 4 which engage in the tab chambers 23 of the rails 2, and elastic profiles 5 with an approximately C-shaped cross section are inserted between the support ribs 4 and the rails 2.
  • the partial plates 3a, 3b are supported with their supporting ribs 4 on the rail foot 6 and laterally against the rail web 7 and held upwards by engagement under the rail head 8.
  • the partial plates 3a, 3b bridge the distance 24 between the rails 2 in a self-supporting manner.
  • a plurality of support ribs 4 are provided on each of the partial plates 3a, 3b, which are arranged at a distance from one another in order to leave the fastening elements 25 provided for the rails 2 accessible.
  • each pair of plates are supported on one another, so that each pair of plates forms an assembled body which bridges the distance 24 between the rails 2 in a self-supporting manner.
  • the support sections 28 being formed by depressions 30 which extend from the top side 12 of the plate and extend to the edge facing the other partial plate; under the support sections 29, starting from the lower side 31 of the plate, upward depressions 32 are formed, and the support sections of the partial plate 3a lie on the supporting sections of the partial plate 3b and the supporting sections of the partial plate 3b rest on the supporting sections of the partial plate 3a;
  • the depressions 30 are complementary to the depressions 32, so that the support surfaces 34 formed on the support sections 29 by the depressions 32 lie substantially snugly on the support surfaces 33 formed by the depressions 30 on the support sections 28.
  • the partial plates 3a, 3b In order to insert the partial plates 3a, 3b in pairs between the rails 2 of a track, they can first be arranged in the unfolded position, as shown in FIG. 9, and in the process they can be inserted into one another with their meandering edges 26, 27 also arranges the elastic profiles 5, which have a C-shaped cross section, between the supporting ribs 4 of the partial plates 3a, 3b and the rails 2. Then the partial plates 3a, 3b are pivoted or folded down, as indicated by the arrow 35, until they assume the leveled position shown in FIGS. 5 to 7, in which the partial plates 3a, 3b of each pair of plates space 22 between bridge the rails 2 in a self-supporting manner.
  • the support surfaces 33 provided in the support sections 28 have a cambered shape, and there is such a cambered shape also in the support surfaces 34 provided on the support sections 29, and this cambered shape of the named surfaces ensures that the partial plates retain their shape 3a, 3b create ge, which in the leveled position of the partial plates 3a, 3b inhibits a mutual movement of these partial plates in the direction of the plate plane (arrows 36).
  • projections 37 are provided on the support surfaces 34 and recesses 38 are provided on the support surfaces 33, which are complementary to the projections 37; in the leveled position of the partial plates, the Projections 37 into the recesses 38, so that there is a mutual locking of the partial plates 3a, 3b.
  • an elastic and / or shock-absorbing insert or coating can be provided between the support surfaces 33 and the support surfaces 34.
  • the supporting surfaces 33 provided on the supporting sections run, starting from the edge 26 or 27 of the respective partial plate 3a or 3b, first rising steeply from the underside 31 of the plate and then becoming flatter, which is advantageous for joining the partial plates to the pairs of plates. From a geometrical point of view, it is favorable if such domed wings are shaped according to a toothing which, up to the leveled position of the partial plates 3a, 3b of the respective plate pair, enables a sliding movement or rolling movement of the mutually facing wings and supporting surfaces on one another, and in the leveled position (Fig. 5 to 7) locks these partial plates against movement to each other.
  • This geometrical shape corresponding to a toothing can extend up to the top 12 of the plate.
  • the projections 37 can, as shown in FIGS. 5 to 8, be provided on the end edges 39 of the support sections 29, which can bring advantages when joining the partial plates, but it is also possible to place such projections 37 elsewhere, e.g. slightly removed from the edge of the support surfaces.
  • the support surfaces 33 and the support surfaces 34 are largely flat; In this case, too, recesses 38, into which projections 37 engage, are provided for mutual locking of the partial plates 3a, 3b.
  • the two partial plates 3a, 3b of a pair of plates lie on one another in a meandering manner on the underside 31 of the plate, so that the mutually facing edges of the partial plates 3a , 3b run on the underside of the plate following a meandering line 43. This results in a very intimate cohesion of the partial plates 3a, 3b forming a pair of plates.
  • the partial plates 3a, 3b are rounded at the mutually facing edges 26, 27 from the underside 31 of the plate upwards, the radius of curvature of this rounding being equal to or smaller than the distance 41 between the edges 26, 27 and the rail-side edges 42 of the partial plates 3a, 3b. This measure is also advantageous for an unrestrained process of inserting the partial plates.
  • the reinforcement 11 provided in the partial plates extends over the entire surface extent of the partial plates 3a, 3b and, as indicated by the broken lines in FIG. 8, both in the support sections 28 and in the support sections 29 as well engages in the support ribs 4.
  • cavity resonators 14 with sound openings 15 can be provided, as is the case e.g. 11 to 14 is shown.
  • the plates can also be provided with frames 44, as is e.g. is indicated by dashed lines in FIG.

Landscapes

  • Architecture (AREA)
  • Civil Engineering (AREA)
  • Structural Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Building Environments (AREA)
  • Soundproofing, Sound Blocking, And Sound Damping (AREA)
  • Railway Tracks (AREA)
  • Power-Operated Mechanisms For Wings (AREA)
  • Devices Affording Protection Of Roads Or Walls For Sound Insulation (AREA)
  • Signal Processing Not Specific To The Method Of Recording And Reproducing (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Magnetic Heads (AREA)
  • Noise Elimination (AREA)
  • Holo Graphy (AREA)
  • Bridges Or Land Bridges (AREA)
PCT/AT1997/000109 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise Ceased WO1997045592A1 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DK97922748T DK0901536T3 (da) 1996-05-29 1997-05-23 Støjdæmpningsindretning til spor
DE59708955T DE59708955D1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise
CA002255946A CA2255946C (en) 1996-05-29 1997-05-23 Track soundproofing arrangement
AT97922748T ATE229595T1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise
EP97922748A EP0901536B1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise
SI9730491T SI0901536T1 (en) 1996-05-29 1997-05-23 Track soundproofing arrangement
JP54125697A JP3822641B2 (ja) 1996-05-29 1997-05-23 軌道用の防音装置
HU9903612A HU221872B1 (hu) 1996-05-29 1997-05-23 Zajvédelmi berendezés vasúti vágányokhoz
US09/194,505 US6253872B1 (en) 1996-05-29 1997-05-23 Track soundproofing arrangement
AU28801/97A AU738889B2 (en) 1996-05-29 1997-05-23 A noise control device for tracks
NO19985600A NO316078B1 (no) 1996-05-29 1998-11-30 Lydisoleringsanordning for skinnespor, samt en lydabsorberende plate for denne

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT93496A AT403809B (de) 1996-05-29 1996-05-29 Schallschutzeinrichtung für gleise
ATA934/96 1996-05-29
AT0101596A AT405426B (de) 1996-06-11 1996-06-11 Schienengleiche eindeckung für gleise
ATA1015/96 1996-06-11

Publications (1)

Publication Number Publication Date
WO1997045592A1 true WO1997045592A1 (de) 1997-12-04

Family

ID=25594370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT1997/000109 Ceased WO1997045592A1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise

Country Status (14)

Country Link
US (1) US6253872B1 (https=)
EP (1) EP0901536B1 (https=)
JP (1) JP3822641B2 (https=)
CN (1) CN100424268C (https=)
AT (1) ATE229595T1 (https=)
AU (1) AU738889B2 (https=)
CA (1) CA2255946C (https=)
DE (1) DE59708955D1 (https=)
DK (1) DK0901536T3 (https=)
ES (1) ES2186891T3 (https=)
HU (1) HU221872B1 (https=)
NO (1) NO316078B1 (https=)
TW (1) TW345603B (https=)
WO (1) WO1997045592A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0945547A1 (de) * 1998-03-21 1999-09-29 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
EP1039032A1 (de) * 1999-03-26 2000-09-27 DVG Deutsche Verpackungsmittel-GmbH Absorptionsbelag zur Reduzierung der Schallabstrahlung für Gleiskörper
US6481637B1 (en) * 2000-11-20 2002-11-19 Mcqueen Philip Jeffrey Rail pad and method for strain attentuation
WO2005085529A1 (de) * 2004-03-05 2005-09-15 Gmundner Fertigteile Gesellschaft M.B.H. & Co. Kg. Störschall mindernde gleiseindeckung
NL2003697C2 (nl) * 2009-10-22 2011-04-26 Univ Twente Weg met geluid-diffractoren.

Families Citing this family (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
DE10111919A1 (de) * 2001-03-13 2002-09-19 Boegl Max Bauunternehmung Gmbh Fahrwegträger
HU224236B1 (hu) * 2001-12-14 2005-06-28 Attila Szebeni Vasúti acélhidaknál alkalmazható, egymáshoz csatlakoztatott elemekbõl álló, zaj- és rezgéscsökkentett mûanyag járólemezrendszer
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
EP1517684B1 (en) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
AT6414U1 (de) * 2002-07-17 2003-10-27 Gmundner Fertigteile Gmbh Gleisabdeckung
GB2399123B (en) * 2003-03-05 2006-03-01 Corus Uk Ltd Rail damper
US20040248877A1 (en) * 2003-04-30 2004-12-09 Sandeep Gupta Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof
WO2004099158A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
JP4847868B2 (ja) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20100126797A1 (en) * 2004-02-12 2010-05-27 Humphries Eric C Panel Assembly For Traffic Noise Barrier Wall
US7546900B2 (en) * 2004-02-12 2009-06-16 Evonik Cyro Llc Panel assembly for traffic noise barrier wall
US8616331B2 (en) 2004-02-12 2013-12-31 Eric C. Humphries Panel assembly for traffic noise barrier wall
KR20070032700A (ko) 2004-05-20 2007-03-22 폴드알엑스 파마슈티칼스, 인크. 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법
EP1802303B1 (en) 2004-09-17 2011-11-02 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
US20070131480A1 (en) * 2004-12-06 2007-06-14 Corbin Maxwell H Jr Sound arresting barrier
US7464791B2 (en) * 2005-01-27 2008-12-16 Pretty Products, Llc Acoustic mats and methods for making the same
US20060230699A1 (en) * 2005-03-22 2006-10-19 Keene James R Sound control flooring systems and methods therefor
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
CA2647543A1 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
AU2007260579B2 (en) * 2006-06-13 2012-09-06 Newstyle Nominees Pty Ltd Rail track crossing
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
PL2066662T3 (pl) 2006-09-21 2013-05-31 Kyorin Seiyaku Kk Inhibitory hydrolaz serynowych
JP2010507585A (ja) 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
JP5013590B2 (ja) * 2006-11-14 2012-08-29 エンデバーハウス株式会社 伸縮性に優れた線路用吸音材
US20080146605A1 (en) 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
CA2671766A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
PT2144604E (pt) 2007-02-28 2011-10-19 Conatus Pharmaceuticals Inc Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
WO2008140859A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
WO2009035634A2 (en) * 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
CN102344457B (zh) 2007-09-12 2015-07-22 杏林制药株式会社 作为 gsk-3 抑制剂的螺环状氨基喹诺酮
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
WO2009059512A1 (en) * 2007-11-07 2009-05-14 Wai Lun Ho Tunable vibration absorbing device
JP2011504485A (ja) * 2007-11-21 2011-02-10 ファーマクシス リミテッド Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
SI2947072T1 (sl) 2008-03-17 2017-03-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
US8048204B2 (en) 2008-09-23 2011-11-01 Rwdi Air Inc. Wall assembly
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
AR075633A1 (es) 2009-02-27 2011-04-20 Ambit Biosciences Corp Compuestos moduladores de jak quinasa y sus metodos de uso
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
BRPI1008974A2 (pt) * 2009-03-11 2017-06-06 Kyorin Seiyaku Kk composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
US8146310B2 (en) * 2009-03-11 2012-04-03 Keene Building Products Co., Inc. Noise control flooring system
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
RU2539591C2 (ru) 2009-04-22 2015-01-20 Аксикин Фармасьютикалз, Инк. Антагонисты арилсульфонамида ccr3
KR101687144B1 (ko) 2009-04-22 2016-12-15 액시킨 파마수티컬스 인코포레이티드 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
EP2727908A3 (en) 2009-04-22 2014-08-20 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AU2010270605B2 (en) 2009-07-08 2014-07-31 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP2461811B1 (en) 2009-08-05 2016-04-20 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
JP2013502429A (ja) 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン ビアリール化合物及びその使用方法
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US8528286B2 (en) * 2009-11-10 2013-09-10 Keene Building Products Co., Inc. Sound control mat
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
KR20120118008A (ko) 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
IN2012DN04858A (https=) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
AU2011223873B2 (en) 2010-03-02 2015-06-25 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
EP2547655B1 (en) 2010-03-17 2016-03-09 Axikin Pharmaceuticals, Inc. Arylsulfonamide ccr3 antagonists
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
JP6019015B2 (ja) 2010-06-01 2016-11-02 ビオトヘルイク， インコーポレイテッド ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法
MX2012013879A (es) 2010-06-01 2013-04-03 Biotheryx Inc Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX2012014273A (es) 2010-06-07 2013-03-22 Novomedix Llc Compuestos furanilo y su uso.
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
EP2611448A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
ES2579942T3 (es) 2010-09-01 2016-08-17 Ambit Biosciences Corporation Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
EP2611793A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030924A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US20130317045A1 (en) 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
EP2611794A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
CN103270030B (zh) 2010-09-01 2016-01-20 埃姆比特生物科学公司 吡唑基氨基喹唑啉的氢溴酸盐
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CN103298786B (zh) 2010-10-11 2016-01-20 埃克希金医药品有限公司 芳基磺酰胺盐ccr3拮抗剂
US20120125711A1 (en) * 2010-11-24 2012-05-24 Stahr Richard E Sound absorbing panel and system
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
JP2014509648A (ja) 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換シクロアルキルアミノ及びヘテロシクリルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、その医薬組成物、並びに増殖性疾患の治療におけるそれらの使用
WO2012135166A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
MX2013015373A (es) 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Nuevos analogos de fluoroergolina.
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
RS54936B1 (sr) 2011-10-14 2016-11-30 Ambit Biosciences Corp Heterociklična jedinjenja i njihova upotreba kao modulatora receptora tirozin kinaza tipa iii
SG11201403434YA (en) 2011-12-19 2014-09-26 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
KR20140138293A (ko) 2012-03-16 2014-12-03 액시킨 파마수티컬스 인코포레이티드 3,5-다이아미노피라졸 키나아제 억제제
EP3438087A1 (en) 2012-05-02 2019-02-06 Boehringer Ingelheim International GmbH Substituted 3-haloallylamine inhibitors of ssao and uses thereof
EP3406598B1 (en) 2012-06-14 2020-01-29 Mayo Foundation for Medical Education and Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
CN104781240A (zh) 2012-09-07 2015-07-15 埃克希金医药品有限公司 同位素富集的芳基磺酰胺ccr3拮抗剂
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
WO2014074765A2 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
CN104955801B (zh) 2012-11-30 2017-10-31 诺沃梅迪科斯有限公司 取代的二芳基磺酰胺及其用途
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
BR112015014964A2 (pt) 2012-12-21 2017-07-11 Map Pharmaceuticals Inc novos derivados de metisergida
CA2897665A1 (en) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamins c and k for treating polycystic diseases
SG11201509982UA (https=) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
US9909269B2 (en) * 2013-07-07 2018-03-06 4Silence B.V. Diffractor for diffracting sound
KR20160055170A (ko) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
KR102409739B1 (ko) 2014-03-20 2022-06-17 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
KR102416358B1 (ko) 2014-03-20 2022-07-07 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
ES2751652T3 (es) 2014-05-12 2020-04-01 Conatus Pharmaceuticals Inc Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
BR112017004708A2 (pt) 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ エルゴリン化合物およびその使用
WO2016119700A1 (en) 2015-01-28 2016-08-04 Jn Therapeutics Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
EA036837B1 (ru) 2015-06-23 2020-12-25 Нейрокрин Байосайенсиз, Инк. Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
MY193767A (en) 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
JP7011596B2 (ja) 2015-12-02 2022-02-10 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
JP2019500397A (ja) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
EP3399981B1 (en) 2016-01-08 2023-08-02 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
CN108430473B (zh) 2016-01-08 2021-08-31 细胞基因公司 抗增殖化合物以及其药物组合物和用途
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10407437B2 (en) 2016-03-08 2019-09-10 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
EP3426301A4 (en) 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. VERBUNDNANOPARTICLES AND USES THEREOF
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
ES2939373T3 (es) 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
DE102016111064A1 (de) * 2016-06-16 2017-12-21 Vossloh-Werke Gmbh Elastisches Element für einen Befestigungspunkt für eine Schiene für Schienenfahrzeuge und Befestigungspunkt
CN106087611B (zh) * 2016-06-20 2019-07-12 勾厚渝 轨道交通构件
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
CN109982687A (zh) 2016-09-19 2019-07-05 梅制药公司 联合疗法
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
TW201828932A (zh) 2016-11-09 2018-08-16 美商諾沃麥迪斯有限責任公司 1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
EP3548007A4 (en) 2016-12-01 2020-08-12 Ignyta, Inc. METHOD OF TREATMENT OF CANCER
TW202345829A (zh) 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
US10961276B2 (en) 2017-02-17 2021-03-30 CAMRIS International, Inc. Universal antivenom
KR102874295B1 (ko) 2017-02-17 2025-10-20 에이도스 테라퓨틱스, 인코포레이티드 Ag-10, 이의 중간체, 및 이의 염을 제조하는 방법
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
BR112019020185A2 (pt) 2017-03-27 2020-06-02 Celgene Corporation Métodos e composições para redução da imunogenicidade
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体及びその用途
JP7012384B2 (ja) 2017-06-27 2022-02-14 ニューラクル サイエンス カンパニー リミテッド 癌治療のための抗ｆａｍ１９ａ５抗体の用途
EP3645039A4 (en) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
WO2019003162A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, MEMBER A5, FOR THE TREATMENT OF GLAUCOMA
AU2018324070B2 (en) 2017-09-01 2023-05-18 East Carolina University Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
US12072339B2 (en) 2017-10-02 2024-08-27 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment and diagnosis of mood disorders
WO2019071021A2 (en) 2017-10-04 2019-04-11 The Regents Of The University Of California IMMUNOMODULATORY OLIGOSACCHARIDES
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
JP7395480B2 (ja) 2018-01-10 2023-12-11 クラ セラピューティクス， エルエルシー フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
US11058668B2 (en) 2018-03-23 2021-07-13 Eidos Therapeutics, Inc. Methods of treating TTR amyloidosis using AG10
CA3097999A1 (en) 2018-04-24 2019-10-31 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
CA3098805A1 (en) 2018-05-10 2019-11-14 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
CN108533609B (zh) * 2018-06-27 2020-03-10 贵州筑信达创科技有限公司 导轨及滑动件的组合结构
CN108836091B (zh) * 2018-06-27 2020-12-04 贵州筑信达创科技有限公司 导轨
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
IL325404A (en) 2018-08-17 2026-02-01 Eidos Therapeutics Inc Spice formulations containing 3-(3-(5,3-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid
WO2020070678A2 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
WO2020079595A1 (en) 2018-10-16 2020-04-23 Neuracle Science Co., Ltd. Use of anti-fam19a5 antibodies
EP3880231A1 (en) 2018-11-16 2021-09-22 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
WO2020118042A1 (en) 2018-12-05 2020-06-11 Jacobs Wagner Christine Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of lyme disease-related pathologies
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
JP7239216B2 (ja) 2018-12-27 2023-03-14 ニューラクル サイエンス カンパニー リミテッド 粥状硬化症を治療するための抗ｆａｍ１９ａ５抗体の使用
CA3117619A1 (en) 2019-01-02 2020-07-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
PL3935042T3 (pl) 2019-03-07 2024-11-04 Nobo Medicine Inc. Inhibitory kaspazy i sposoby ich zastosowania
EP3959292B1 (en) 2019-05-20 2025-07-02 NIRvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
US20220249707A1 (en) 2019-05-20 2022-08-11 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
CA3146159A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
EP3997068A1 (en) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
IL291345B2 (en) 2019-09-16 2024-04-01 Dice Alpha Inc Il-17a modulators and uses thereof
KR102337657B1 (ko) * 2019-11-06 2021-12-09 한국철도기술연구원 철도진동저감용 조립식 블록 및 이를 이용한 블록 구조물
IL294663A (en) 2020-01-13 2022-09-01 Neoimmunetech Inc Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
CN113136745B (zh) * 2020-01-17 2024-10-25 洛阳双瑞橡塑科技有限公司 一种轨道道床吸音减振装置
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
US12006643B2 (en) * 2020-05-27 2024-06-11 Mute Wall Systems, Inc. Sound dampening barrier wall
WO2021242970A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
EP4168414A1 (en) 2020-06-18 2023-04-26 Shy Therapeutics LLC Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP7828905B2 (ja) 2020-06-30 2026-03-12 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022094475A1 (en) 2020-11-02 2022-05-05 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
CA3195594A1 (en) 2020-11-05 2022-05-12 Byung Ha Lee Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
CN112712784B (zh) * 2020-11-30 2024-12-31 南京华秦光声科技有限责任公司 一种低频宽带平板吸声结构
TW202237580A (zh) 2020-12-14 2022-10-01 美商拜歐斯瑞克斯公司 Pde4降解劑、醫藥組合物及治療應用
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
EP4284377A1 (en) 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
CR20230472A (es) 2021-03-10 2024-03-21 Dice Molecules Sv Inc Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
WO2022251533A1 (en) 2021-05-27 2022-12-01 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
AU2022292649A1 (en) 2021-06-16 2024-01-04 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20240277857A1 (en) 2021-09-29 2024-08-22 Nbios, Inc. Coiled-coil fusion protein
US12017997B2 (en) 2021-10-22 2024-06-25 Prosetta Biosciences, Inc. Host-targeted pan-respiratory antiviral small molecule therapeutics
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
KR20240130705A (ko) 2021-12-30 2024-08-29 네오이뮨텍, 인코퍼레이티드 Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
EP4433040A4 (en) 2022-01-03 2025-11-12 Lilac Therapeutics Inc ACYCLIC THIOL PRODRUGS
AU2022441090A1 (en) 2022-02-17 2024-08-22 Novelty Nobility Inc. Antibody-drug conjugate.
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー， インク． ニコチン酸及びリボースから誘導体化した新規プロドラッグ
AR128918A1 (es) 2022-03-30 2024-06-26 Biomarin Pharm Inc Oligonucleótidos que omiten el exón 51 de distrofina y sus aplicaciones
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
WO2023201282A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
WO2023215781A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
TW202413356A (zh) 2022-05-10 2024-04-01 美商拜歐斯瑞克斯公司 Ｃｄｋ蛋白降解劑、藥物組合物及其治療應用
KR20250027283A (ko) 2022-05-19 2025-02-25 라이엘 이뮤노파마, 인크. nr4a3을 표적하는 폴리뉴클레오타이드 및 이의 용도
CN120303264A (zh) 2022-09-09 2025-07-11 医诺康治疗公司 CK1α和双重CK1α/GSPT1降解化合物
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
US20240209100A1 (en) 2022-10-21 2024-06-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
WO2024092043A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
EP4608838A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
EP4608839A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
KR102870410B1 (ko) * 2022-12-09 2025-10-16 한국전자기술연구원 방음재 및 소음 제어 시스템
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
US20240383990A1 (en) 2023-04-07 2024-11-21 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
US20240368596A1 (en) 2023-05-05 2024-11-07 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
CN121263415A (zh) 2023-05-09 2026-01-02 普罗根托斯治疗公司 杂环化合物及其用途
CN121219320A (zh) 2023-05-19 2025-12-26 达科纳治疗有限公司 针对il12受体的双特异性激动性抗体
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
US20250122182A1 (en) 2023-09-27 2025-04-17 Isosterix, Inc. MYST Inhibitors
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
AU2024366926A1 (en) 2023-10-23 2026-03-12 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators
WO2026080752A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. De novo antibodies to activin a receptor like type 1 (alk1)
WO2026080748A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Bone morphogenetic protein receptor type 2 (bmprii) antibodies
WO2026080757A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Activin receptor type ii a/b (actriia/b) antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2350759A1 (de) * 1973-10-10 1975-04-24 Straetner Geb Buss Anita Abdeckplatte fuer gleisanlagen
DE3602313A1 (de) * 1986-01-27 1987-07-30 Clouth Gummiwerke Ag Schallabsorbierender laermschutz insbesondere fuer schotterlose gleise
DE4243102A1 (en) * 1991-12-20 1993-07-01 Bold Karl Gmbh & Co Noise protection and sight wall with carrier girder construction
DE29515935U1 (de) * 1995-10-07 1995-11-30 Deutsche Asphalt GmbH, 63263 Neu-Isenburg Schallabsorber für einen schotterlosen Eisenbahnoberbau
NL9400910A (nl) * 1994-06-06 1996-01-02 Veldhoen Raalte B V Samenstel voor de geluidsisolatie van een spoorbaan.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991848A (en) * 1974-08-16 1976-11-16 Frigitemp Acoustical board
US4142468A (en) * 1976-04-20 1979-03-06 Charles Birnstiel Elevated rail transit guideway with noise attenuators
US4093120A (en) 1977-01-24 1978-06-06 Park Rubber Company Railroad crossing structure
DE7711191U1 (de) 1977-04-07 1978-09-28 Straetner Geb. Buss, Anita, 4300 Essen Fahrbahnplatte fuer schienengleiche bahnuebergaenge
DE2727644C2 (de) * 1977-06-20 1983-06-30 Gummiwerk Kraiburg Elastik Gmbh & Co, 8261 Tittmoning Schienengleicher Bahnübergang
DE3827547C2 (de) * 1988-08-13 2000-09-21 Zueblin Ag Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
US4960184A (en) * 1989-11-09 1990-10-02 Bruce Woodward Sound absorbing structure
US5730548A (en) * 1994-02-11 1998-03-24 Autostrade-Concessioni E Costruzioni Autostrade S.P.A. Deadening road pavement and method for its realization
DE4414566C2 (de) * 1994-04-27 1997-11-20 Freudenberg Carl Fa Luftschalldämpfer
DE4417402A1 (de) 1994-05-18 1995-11-23 Gruenzweig & Hartmann Montage Schallschutzeinrichtung zur Schalldämpfung und -dämmung an Gleiskörpern
IT1293307B1 (it) * 1997-07-09 1999-02-16 Dieselbox Sa Barriera antirumore a pannelli trasparenti,dotata di caratteristiche fonoisolanti e fonoassorbenti

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2350759A1 (de) * 1973-10-10 1975-04-24 Straetner Geb Buss Anita Abdeckplatte fuer gleisanlagen
DE3602313A1 (de) * 1986-01-27 1987-07-30 Clouth Gummiwerke Ag Schallabsorbierender laermschutz insbesondere fuer schotterlose gleise
DE4243102A1 (en) * 1991-12-20 1993-07-01 Bold Karl Gmbh & Co Noise protection and sight wall with carrier girder construction
NL9400910A (nl) * 1994-06-06 1996-01-02 Veldhoen Raalte B V Samenstel voor de geluidsisolatie van een spoorbaan.
DE29515935U1 (de) * 1995-10-07 1995-11-30 Deutsche Asphalt GmbH, 63263 Neu-Isenburg Schallabsorber für einen schotterlosen Eisenbahnoberbau

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0945547A1 (de) * 1998-03-21 1999-09-29 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
DE19812481A1 (de) * 1998-03-21 1999-09-30 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
WO1999049134A1 (de) * 1998-03-21 1999-09-30 Johann Rath Vorrichtung zur dämpfung von schallemissionen an gleisanlagen
DE19812481C2 (de) * 1998-03-21 2002-08-22 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
EP1039032A1 (de) * 1999-03-26 2000-09-27 DVG Deutsche Verpackungsmittel-GmbH Absorptionsbelag zur Reduzierung der Schallabstrahlung für Gleiskörper
US6481637B1 (en) * 2000-11-20 2002-11-19 Mcqueen Philip Jeffrey Rail pad and method for strain attentuation
WO2005085529A1 (de) * 2004-03-05 2005-09-15 Gmundner Fertigteile Gesellschaft M.B.H. & Co. Kg. Störschall mindernde gleiseindeckung
AU2005219446B2 (en) * 2004-03-05 2010-11-11 Gmundner Fertigteile Gesellschaft M.B.H. & Co. Kg Noise reducing track covering
NL2003697C2 (nl) * 2009-10-22 2011-04-26 Univ Twente Weg met geluid-diffractoren.
WO2011049454A2 (en) 2009-10-22 2011-04-28 Universiteit Twente Road with sound diffractors
WO2011049454A3 (en) * 2009-10-22 2012-05-18 Universiteit Twente Road with sound diffractors
US8696233B2 (en) 2009-10-22 2014-04-15 4Silence B.V. Road with sound diffractors

Also Published As

Publication number Publication date
TW345603B (en) 1998-11-21
JP3822641B2 (ja) 2006-09-20
HUP9903612A3 (en) 2001-08-28
NO985600D0 (no) 1998-11-30
CA2255946C (en) 2006-03-14
NO316078B1 (no) 2003-12-08
US6253872B1 (en) 2001-07-03
JP2000510921A (ja) 2000-08-22
AU738889B2 (en) 2001-09-27
DE59708955D1 (de) 2003-01-23
EP0901536A1 (de) 1999-03-17
HU221872B1 (hu) 2003-02-28
DK0901536T3 (da) 2003-04-07
ES2186891T3 (es) 2003-05-16
EP0901536B1 (de) 2002-12-11
NO985600L (no) 1998-11-30
ATE229595T1 (de) 2002-12-15
CA2255946A1 (en) 1997-12-04
CN1219989A (zh) 1999-06-16
AU2880197A (en) 1998-01-05
HUP9903612A2 (hu) 2000-02-28
CN100424268C (zh) 2008-10-08

Similar Documents

Publication Publication Date Title
EP0901536B1 (de) Schallschutzeinrichtung für gleise
EP0904461B1 (de) Schienengleiche eindeckung für gleise
DE2537408C3 (de) Baustein zur Herstellung einer bepflanzbaren Stützmauer
EP0214524B1 (de) Mauerwerk- oder Pflasterstein aus Beton oder dergleichen
WO2013075159A1 (de) Lärmschutzvorrichtung
DE19705531A1 (de) Vorrichtung zur Überbrückung von Dehnfugen
DE4430769C2 (de) Eisenbahnoberbau mit einem auf einer durchgehenden Tragplatte aus Stahlbeton aufgelagerten Gleisrost
DE3134473A1 (de) Schotterloser oberbau fuer schienenbahnen
DE3827547C2 (de) Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
DE202011052057U1 (de) Lärmschutzvorrichtung
DE19514458A1 (de) Schallabsorbierendes Wandelement
DE3727947C2 (https=)
EP2817456B1 (de) Lärmschutzvorrichtung
DE3544481A1 (de) Schallschutzwand und dafuer geeignetes wandelement
AT403809B (de) Schallschutzeinrichtung für gleise
DE19540357C1 (de) Eisenbahnbrücke und Kulisse zur Schalldämpfung an dieser
DE19635788A1 (de) Schalldämpfungselement für Schienentrassen mit fester Fahrbahn
EP1136622B1 (de) Gleiseindeckung
EP0166719A2 (de) Profildichtung
WO2005085529A1 (de) Störschall mindernde gleiseindeckung
AT512391B1 (de) Lärmschutzvorrichtung
DE2856367A1 (de) Plattenbelag fuer daecher sowie tragelemente fuer diese
DE2607538A1 (de) Verbundformsteinelement
EP1170419A2 (de) Schallgedämmter, schotterloser Gleisoberbau sowie Schallabsorptionselement
AT386852B (de) Profildichtung

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97195049.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2255946

Country of ref document: CA

Ref document number: 2255946

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09194505

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1997922748

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 9070

Country of ref document: AT

Date of ref document: 19971204

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 19979070

Country of ref document: AT

WWP Wipo information: published in national office

Ref document number: 1997922748

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1997922748

Country of ref document: EP